Calidi Biotherapeutics, Inc.
No SEC Form 4 filings for $CLDI in the last 30 days.
See all $CLDI insider activity →Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs
Calidi Biotherapeutics (NYSE: CLDI) shares rose after the company recapped 2026 progress and outlined upcoming milestones. Calidi said it held a successful pre-IND meeting with the FDA for CLD-401, discussed pharmacology, toxicology, CMC and phase I strategy, and is advancing in situ TCEs. It also added Corsee Sanders to the board and cut debt and G&A by about $1M in 1Q26 vs 1Q25.
Calidi Biotherapeutics (NYSE American: CLDI) reported a positive US FDA pre-IND outcome for CLD-401, agreeing on pharmacology, toxicology, CMC and phase I protocol strategy. The company targets first patient dosing in Q1 2027 and expects first data in Q2 2027. It also cited new RedTail in situ TCE data, added a board member, and cut G&A by about $1M from Q1 2025 to Q1 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning CLDI (Calidi Biotherapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CLDI coverage spans financial news, corporate actions and earnings.
FDA pre-IND alignment reduces regulatory uncertainty for CLD-401’s Phase 1 start, supporting near-term sentiment and risk appetite for the name.
FDA pre-IND alignment reduces regulatory uncertainty for CLD-401 and supports the company’s stated IND filing timeline.
FDA pre-IND alignment reduces regulatory uncertainty for CLD-401 and supports the company’s planned IND filing and Phase I start timeline.
The filing is a balance-sheet and cash-flow overhang via fixed lease commitments and a required letter of credit, but it is not a clinical or financing catalyst.
Board appointment is a governance/credibility signal for a pre-clinical/IND-enabling biotech, but it does not change near-term clinical timelines in the release.
alphai scores every news story that mentions CLDI with an AI model for sentiment and relevance, and aggregates insider trades from Calidi Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs
4 min readCalidi Biotherapeutics (NYSE: CLDI) shares rose after the company recapped 2026 progress and outlined upcoming milestones. Calidi said it held a successful pre-IND meeting with the FDA for CLD-401, discussed pharmacology, toxicology, CMC and phase I strategy, and is advancing in situ TCEs. It also added Corsee Sanders to the board and cut debt and G&A by about $1M in 1Q26 vs 1Q25.
3 min readCalidi Biotherapeutics (NYSE American: CLDI) reported a positive US FDA pre-IND outcome for CLD-401, agreeing on pharmacology, toxicology, CMC and phase I protocol strategy. The company targets first patient dosing in Q1 2027 and expects first data in Q2 2027. It also cited new RedTail in situ TCE data, added a board member, and cut G&A by about $1M from Q1 2025 to Q1 2026.
4 min readCalidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 GENESIS MOREHOUSE AT 5580 LEASE BP3-SD4 5580 MOREHOUSE DRIVE LLC, a Delaware limited liability company, as Landlord, and CALIDI BIOTHERAPEUTICS, INC., a Delaware corporation, as Tenant SUMMARY OF BASIC LEASE INFORMATION This Summary of Ba
6 min readCalidi Biotherapeutics (NYSE American: CLDI) said it appointed Corsee Sanders, Ph.D., an independent director, to its board effective June 17, 2026. Calidi cited her 30+ years in biopharma clinical operations, including leadership roles at Genentech/Roche and Celgene/Juno integration experience. The company said the move supports advancement of CLD-401 and its RedTail platform into the clinic.
2 min readCalidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001855485 0001855485 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readCalidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001855485 0001855485 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readCalidi Biotherapeutics (NYSEAMERICAN:CLDI) reported short interest fell to 670,614 shares as of May 15, down 77.9% from 3,038,967 on April 30, with 6.4% of shares sold short and a 0.3 days-to-cover ratio. The stock traded at $0.19, down 2.6%. The company reported EPS of -$0.43 for the quarter ended May 14, and institutional holders own 12.53%.
4 min readSAN DIEGO, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Calidi Biotherapeutics, Inc. ( "Calidi" or the "Company" ) ( NYSE American: CLDI ) , a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, ...
2 min readSAN DIEGO, July 25, 2025 ( GLOBE NEWSWIRE ) -- Calidi Biotherapeutics, Inc. ( "Calidi" or the "Company" ) ( NYSE American: CLDI ) , a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, ...
3 min read
